Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.43 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.43 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 4/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18493281 | 0.90 | LMNA (0.55) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL18512579 | 0.86 | LMNA (0.55) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL17213531 | 0.85 | LMNA (0.57) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL18512526 | 0.84 | LMNA (0.54) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL14075778 | 0.83 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13046095 | 0.83 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13084357 | 0.83 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL13863569 | 0.83 | LMNA (0.75) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL29672348 | 0.83 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ENPP1 | |
| SCHEMBL29672354 | 0.83 | LMNA (0.64) | LMNAP2RX3P2RX4P2RX2ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | LMNA 2227/4885P2RX3 54/4885P2RX4 67/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | LMNA 2579/4885P2RX3 54/4885P2RX4 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.